Skip to main content

#Mpox, Multi-country external #situation #report no. 54 published 27 June (#WHO)

Image
By G.M.



{Summary)

KEY FIGURES 

{Area - Number of reported confirmed cases - Number of deaths among confirmed cases - Number of reporting countries}

-- Global (1 Jan – 31 May 2025)* - 24 672 - 82 - 75 

Key countries (01 Jan – 22 June 2025)

- Democratic Republic of the Congo - 12 208 - 22 - ...

- Uganda - 5636 - 31  - ...

- Sierra Leone - 4294 - 28 - ...

- Burundi - 1079 - 0 - ...

{*} Most recent global surveillance data available.


Highlights

• In May 2025, a total of 6823 confirmed mpox cases and 16 deaths (Case Fatality Ratio: 0.2%) were reported from 49 countries across all WHO regions.

• The majority of mpox cases continue to be reported from the WHO African Region, with 18 countries currently experiencing active ongoing transmission.

• Since the last report, Ethiopia and Italy have reported their first cases of mpox due to clade Ib monkeypox virus (MPXV). In addition, North Macedonia, the Republic of the Congo, and Togo have reported their first cases of mpox clade IIb MPXV. Albania has reported its first mpox case, and genomic sequencing analysis is underway to determine the clade.

• Community transmission of clade Ib MPXV remains limited to countries in Central and East Africa.

• In Sierra Leone, the epidemic trend is consistently declining, although recent data should be interpreted with caution due to reporting delays.

• Eleven African countries have received mpox vaccines, of which seven have started mpox vaccination. More than 731 000 doses of the MVA-BN vaccine have been administered to date.

• WHO has updated its guideline on clinical management and infection prevention and control for mpox.

• The WHO Director-General determined that the ongoing upsurge of mpox continues to constitute a public health emergency of international concern (PHEIC), following the fourth meeting of the International Health Regulations (IHR) Emergency Committee on 5 June 2025.

(...)

Source: World Health Organization, https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report--54---27-june-2025

____

Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »